The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

Parato, 2009, Diplomatic immunity: turning a foe into an ally, Curr Opin Mol Ther, 11, 13

Cattaneo, 2008, Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded, Nat Rev Microbiol, 6, 529, 10.1038/nrmicro1927

Bell, 2003, Getting oncolytic virus therapies off the ground, Cancer Cell, 4, 7, 10.1016/S1535-6108(03)00170-3

Liu, 2008, Development of targeted oncolytic virotherapeutics through translational research, Expert Opin Biol Ther, 8, 1381, 10.1517/14712598.8.9.1381

Liu, 2007, Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress, Nat Clin Pract Oncol, 4, 101, 10.1038/ncponc0736

Stojdl, 2000, Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus, Nat Med, 6, 821, 10.1038/77558

Stojdl, 2003, VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents, Cancer Cell, 4, 263, 10.1016/S1535-6108(03)00241-1

Coffey, 1998, Reovirus therapy of tumors with activated Ras pathway, Science, 282, 1332, 10.1126/science.282.5392.1332

Norman, 2000, Reovirus as a novel oncolytic agent, J Clin Invest, 105, 1035, 10.1172/JCI9871

Bischoff, 1996, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells, Science, 274, 373, 10.1126/science.274.5286.373

Heise, 2000, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy, Nat Med, 6, 1134, 10.1038/80474

Peng, 2002, Intraperitoneal therapy of ovarian cancer using an engineered measles virus, Cancer Res, 62, 4656

Grote, 2001, Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice, Blood, 97, 3746, 10.1182/blood.V97.12.3746

Mineta, 1995, Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas, Nat Med, 1, 938, 10.1038/nm0995-938

Mineta, 1994, Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant, Cancer Res, 54, 3963

Kirn, 2009, Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer, Nat Rev Cancer, 9, 64, 10.1038/nrc2545

Chung, 1998, A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate, J Virol, 72, 1577, 10.1128/JVI.72.2.1577-1585.1998

Laliberte, 2009, Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry, Proc Natl Acad Sci USA, 106, 17517, 10.1073/pnas.0909376106

Mastrangelo, 1999, Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma, Cancer Gene Ther, 6, 409, 10.1038/sj.cgt.7700066

Kim, 2006, Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF, Mol Ther, 14, 361, 10.1016/j.ymthe.2006.05.008

Dranoff, 1993, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc Natl Acad Sci USA, 90, 3539, 10.1073/pnas.90.8.3539

Park, 2008, Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial, Lancet Oncol, 9, 533, 10.1016/S1470-2045(08)70107-4

Breitbach, 2011, Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans, Nature, 477, 99, 10.1038/nature10358

McCart, 2001, Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes, Cancer Res, 61, 8751

Thorne, 2007, Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963, J Clin Invest, 117, 3350, 10.1172/JCI32727

Kirn, 2007, Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus, PLoS Med, 4, e353, 10.1371/journal.pmed.0040353

Foloppe, 2008, Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus, Gene Ther, 15, 1361, 10.1038/gt.2008.82

Zhang, 2009, The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation, Mol Genet Genomics, 282, 417, 10.1007/s00438-009-0475-1

Hengstschläger, 1998, Thymidine kinase expression. A marker for malignant cells, Adv Exp Med Biol, 431, 455, 10.1007/978-1-4615-5381-6_90

Luker, 2005, Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread, Virology, 341, 284, 10.1016/j.virol.2005.06.049

Connolly, 2003, Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer, Cancer Res, 63, 1389

Yang, 2005, Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction, J Clin Invest, 115, 379, 10.1172/JCI200523220

Brown, 1985, Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor, Nature, 313, 491, 10.1038/313491a0

Alcami, 2000, Soluble chemokine binding proteins are also encoded by herpesviruses, Immunol Today, 21, 526, 10.1016/S0167-5699(00)01632-7

Langhammer, 2011, Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa), Antiviral Res, 89, 64, 10.1016/j.antiviral.2010.11.006

Buller, 1985, Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype, Nature, 317, 813, 10.1038/317813a0

Eramo, 2008, Identification and expansion of the tumorigenic lung cancer stem cell population, Cell Death Differ, 15, 504, 10.1038/sj.cdd.4402283

Li, 2004, Pancreatic cancer, Lancet, 363, 1049, 10.1016/S0140-6736(04)15841-8

Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017

Yazdi, 2003, Mutations of the BRAF gene in benign and malignant melanocytic lesions, J Invest Dermatol, 121, 1160, 10.1046/j.1523-1747.2003.12559.x

Walther, 2009, Genetic prognostic and predictive markers in colorectal cancer, Nat Rev Cancer, 9, 489, 10.1038/nrc2645

Giaccone, 2011, Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors, Cancer Treat Rev, 37, 456

Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 26, 1626, 10.1200/JCO.2007.14.7116

Douglas, 2001, Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors, Cancer Res, 61, 813

Weislow, 1989, New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity, J Natl Cancer Inst, 81, 577, 10.1093/jnci/81.8.577

Eramo, 2008, Identification and expansion of the tumorigenic lung cancer stem cell population, Cell Death Differ, 15, 504, 10.1038/sj.cdd.4402283

Ricci-Vitiani, 2007, Identification and expansion of human colon-cancer-initiating cells, Nature, 445, 111, 10.1038/nature05384